Ken Griffin Kal Vista Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $70,004 - $113,886	-7,400 Reduced 79.57%	1,900 $22,000
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $65,205 - $78,687	-6,300 Reduced 40.38%	9,300 $109,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $381,915 - $553,380	-34,500 Reduced 68.86%	15,600 $185,000
Q4 2023 Feb 14, 2024	BUY	$7.58 - $12.25 $269,848 - $436,100	35,600 Added 245.52%	50,100 $613,000
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $124,404 - $157,765	13,900 Added 2316.67%	14,500 $139,000
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $773 - $1,057	-100 Reduced 14.29%	600 $5,000
Q1 2023 May 15, 2023	SELL	$6.3 - $8.39 $24,570 - $32,721	-3,900 Reduced 84.78%	700 $5,000
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $851,340 - $2.89 Million	-202,700 Reduced 97.78%	4,600 $31,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $1.66 Million - $2.83 Million	-168,400 Reduced 44.82%	207,300 $3.01 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.